How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Endothelial Keratoplasty (EK) Market
- By Procedure Type: Descemet's Stripping Endothelial Keratoplasty (DSEK), Descemet Membrane Endothelial Keratoplasty (DMEK), Pre-Descemet Endothelial Keratoplasty (PDEK), Descemet Stripping Automated Endothelial Keratoplasty (DSAEK)
- By End-User: Hospitals, Specialty Eye Clinics, Ambulatory Surgical Centers, Ophthalmology Clinics
- By Indication: Fuchs Endothelial Dystrophy, Bullous Keratopathy, Corneal Endothelial Dysfunction, Posterior Polymorphous Corneal Dystrophy
- By Donor Tissue Source: Whole Corneal Tissue, Pre-cut Donor Tissue, Surgeon-Prepared Tissue
- By Surgical Technique: Manual EK, Automated EK, Femtosecond Laser-Assisted EK
Top segment
Descemet's Stripping Endothelial Keratoplasty (DSEK) XX% share · $X,XXXM
In the full report →
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Descemet's Stripping Endothelial Keratoplasty (DSEK) leads By Procedure Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 13 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 284 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.174 →
- 12 Company Profiles 13 players: SWOT & benchmarking p.182 →
Full report · locked preview
Everything inside the Endothelial Keratoplasty (EK) Market report
A complete, evidence-based study - 12 chapters and 119 sections covering market size, segmentation across 5 axes, regional analysis and 13 company profiles, forecast to 2033.
Segmentation covered
Procedure Type 4
End-User 4
Indication 4
Donor Tissue Source 3
Surgical Technique 3
Companies profiled
Abbott Laboratories
Bausch + Lomb (a division of Bausch Health Companies)
Alcon (a Novartis company)
CorneaGen
Glaukos Corporation
Moria Surgical
Hoya Corporation
Santen Pharmaceutical Co. Ltd.
Carl Zeiss Meditec AG
Nidek Co. Ltd.
Eversight
TissueTech Inc.
+1 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
13 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Abbott Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Bausch + Lomb (a division of Bausch Health Companies)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Alcon (a Novartis company)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →CorneaGen
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Glaukos Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Moria Surgical
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.184 →Hoya Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Santen Pharmaceutical Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Carl Zeiss Meditec AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Nidek Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Eversight
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.214 →TissueTech Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.220 →SightLife
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$8,085M by 2033 · 9.8% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Descemet's Stripping Endothelial Keratoplasty (DSEK)51.4
- Descemet Membrane Endothelial Keratoplasty (DMEK)18.9
- Pre-Descemet Endothelial Keratoplasty (PDEK)15.6
- Descemet Stripping Automated Endothelial Keratoplasty (DSAEK)14.1
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,260M → $2,681M · 9.9%
Europe$878.4M → $2,013M · 10.9%
Asia Pacific$802.1M → $1,549M · 8.6%
Latin America$496.5M → $1,145M · 11.0%
Middle East and Africa$381.9M → $863.9M · 10.7%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →9.782026
9.792027
9.812028
9.822029
9.842030
9.832031
9.852032
9.862033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Abbott Laboratories21.1
- Bausch + Lomb (a division of Bausch Health Companies)18.1
- Alcon (a Novartis company)8.2
- CorneaGen10.7
- Glaukos Corporation8.1
- Moria Surgical5.9
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Procedure Type19.2%
End-User17.2%
Indication20.0%
Donor Tissue Source25.1%
Surgical Technique18.6%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.5
- Europe24.4
- Asia Pacific18.8
- Latin America13.9
- Middle East and Africa10.5
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | 96 | 76 | 94 | 83 | 96 | 76 | 87 |
| Bausch + Lomb (a division of Bausch Health Companies) | 88 | 73 | 85 | 72 | 86 | 72 | 79 |
| Alcon (a Novartis company) | 78 | 69 | 76 | 63 | 75 | 86 | 75 |
| CorneaGen | 67 | 69 | 64 | 71 | 58 | 77 | 68 |
| Glaukos Corporation | 64 | 74 | 55 | 68 | 73 | 74 | 68 |
| Moria Surgical | 58 | 71 | 53 | 50 | 67 | 48 | 58 |
| Hoya Corporation | 45 | 52 | 57 | 54 | 41 | 44 | 49 |
| Santen Pharmaceutical Co. Ltd. | 37 | 50 | 55 | 42 | 37 | 50 | 45 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Abbott Laboratories
- Bausch + Lomb (a division of Bausch Health Companies)
- Alcon (a Novartis company)
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Abbott Laboratories | ✓ | ✓ | ◐ | ✓ | ✓ | ✓ |
| Bausch + Lomb (a division of Bausch Health Companies) | ◐ | ✓ | ◐ | ✓ | ◐ | ◐ |
| Alcon (a Novartis company) | ✓ | ◐ | ◐ | ◐ | − | ✓ |
| CorneaGen | ◐ | ✓ | ◐ | ✓ | − | ✓ |
| Glaukos Corporation | − | ◐ | ◐ | − | ✓ | ◐ |
| Moria Surgical | − | ✓ | − | − | ◐ | − |
| Hoya Corporation | − | ◐ | − | ◐ | ◐ | − |
| Santen Pharmaceutical Co. Ltd. | − | ◐ | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Abbott Laboratories87
2Bausch + Lomb (a division of Bausch Health Companies)79
3Alcon (a Novartis company)75
4CorneaGen68
5Glaukos Corporation68
6Moria Surgical58
7Hoya Corporation49
8Santen Pharmaceutical Co. Ltd.45
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Abbott LaboratoriesBausch + Lomb (a division of Bausch Health Companies)
Challenger3
Strong scale, closing on the leaders.
Alcon (a Novartis company)CorneaGenGlaukos Corporation
Contender1
Focused players with pockets of strength.
Moria Surgical
Niche2
Specialists in a single segment or region.
Hoya CorporationSanten Pharmaceutical Co. Ltd.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Procedure Type in North America, then scale across Endothelial Keratoplasty (EK) Market — a $409M beachhead inside a $5.55B market.
Beachhead (SOM)$409Mobtainable near-term
Serviceable (SAM)$2.20Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion88 fit
Descemet's Stripping Endothelial Keratoplasty (DSEK)
Best fit — highest urgency & budget in Procedure Type.
Economic buyer77 fit
Descemet Membrane Endothelial Keratoplasty (DMEK)
Strong fit — clear ROI and a fast path to value.
End user68 fit
Pre-Descemet Endothelial Keratoplasty (PDEK)
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Procedure Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add End-User & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Indication
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel28%
Digital / self-serve21%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Procedure Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Endothelial Keratoplasty (EK) Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified44%
Sales qualified22%
Evaluation15%
Closed-won6%
$16.5KCAC
$62KLTV
3.8:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Endothelial Keratoplasty (EK) Market is a resilient opportunity — $7.00B by 2033, compounding at 3.4%.
TAM · 2025$5.37Btoday
TAM · 2033$7.00Bforecast
CAGR3.4%2027–2033
Cumulative$55.4Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$7.00BTotal addressable market
SAM$2.58BServiceable available market
SOM$419MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →3.4% CAGR
Demand compounds through 2033, outpacing GDP across Procedure Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Procedure Type moving from early to mainstream — durable secular demand.
Consolidation upside
13+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$7.00BLarge & growingTAM by 2033 at 3.4% CAGR
$2.58BServiceable nowreachable with today’s model
$419MBeachhead winobtainable near-term share
13+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$5.46BBear2.2% CAGR
$7.00BBase3.4% CAGR
$8.95BBull4.4% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & End-User optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Endothelial Keratoplasty (EK) Market — a $2.45B market by 2033. Plan: grow share from 5.3% to 11.3%.
Market size · 2033$2.45Btotal addressable
Market CAGR5.5%2027–2033
Target share11.3%from 5.3% today
Revenue ambition$277Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 5.3% | 11.3% | At risk |
| Revenue | $133M | $277M | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Behind |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | At risk |
| Gross margin | 30.7% | 45.9% | At risk |
| Customer retention | 88.9% | 96.8% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Procedure Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build End-User capability
A defensible second engine — invest in End-User to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Procedure Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch End-User
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $39M capacity & capability investment
- Greenlight bolt-on M&A in End-User
- Authorise North America expansion plan
- Fund R&D program for Procedure Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossBehind
- Input-cost & supply riskAt risk
- Regulatory / policy changeOn track
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Endothelial Keratoplasty (EK) Market conversation — a $4.89B market you can size, segment and defend in minutes.
Market size · 2033$4.89Btotal opportunity
Growth5.0%CAGR to 2033
Addressable buyers1,733+accounts in scope
Typical ROI6.5×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Procedure Type
Goal Grow share in Procedure Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.5×return on cost, year one
< 2 mopayback period
$52K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
13+players profiled in this market
Coverage includes
Abbott LaboratoriesBausch + Lomb (a division of Bausch Health Companies)Alcon (a Novartis company)CorneaGenGlaukos CorporationMoria SurgicalHoya CorporationSanten Pharmaceutical Co. Ltd.+5 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Endothelial Keratoplasty (EK) Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Endothelial Keratoplasty (EK) Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Endothelial Dysfunction Market
Market size, share, segmentation and regional forecast.
$5.3B market · 2025 base year
View reportEndothelial Cell Growth Supplement (ECGS) Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportHygienic Nonwoven Fabric Market
Market size, share, segmentation and regional forecast.
$4.2B market · 2025 base year
View reportEndothelial Cell Basal Medium Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportEndosseous Implant Market
Market size, share, segmentation and regional forecast.
$4.9B market · 2025 base year
View reportEndoskeletal Component Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportEndoscopy Water Delivery Device Market
Market size, share, segmentation and regional forecast.
$4.2B market · 2025 base year
View reportEndoscopy Video Systems Market
Market size, share, segmentation and regional forecast.
$2.1B market · 2025 base year
View reportEndoscopy Video Recorder Market
Market size, share, segmentation and regional forecast.
$626M market · 2025 base year
View reportEndoscopy Ultrasound Market
Market size, share, segmentation and regional forecast.
$925M market · 2025 base year
View reportEndoscopy Software Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportEndoscopy Procedures Estimates Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.